



Dedicated To Life

November 6, 2023

Listing Department <b>BSE LIMITED</b> P J Towers, Dalal Street, Fort, Mumbai-400 001	<b>Code: 532321</b>	Listing Department <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400 051	<b>Code: ZYDUSLIFE</b>
--	---------------------	--	------------------------

Re.: **Acquisition**

Ref.: 1. **Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated July 13, 2023**

2. **Our earlier letters both dated October 31, 2023**

Dear Sir / Madam,

With reference to the captioned subject and further to our earlier letters both dated October 31, 2023, we would like to inform that the transaction of acquisition by Zydus Pharmaceuticals UK Limited, (a wholly owned subsidiary of Zydus Lifesciences Limited) of entire share capital of the Target Companies from the Sellers is consummated today i.e. November 6, 2023.

The transaction was considered as closed at 2.49 p.m. on November 6, 2023.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,  
For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary**

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

